
RNAZ
TransCode
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
stock price surged significantly
consensus rating "Strong Buy"
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About RNAZ
Transcode Therapeutics, Inc.
An oncology based biotech company that develops RNA therapeutics for the treatment of tumor
Biological Technology
01/11/2016
07/09/2021
NASDAQ Stock Exchange
7
12-31
Common stock
6 Liberty Square, #2382, Boston, MA 02109
--
TransCode Therapeutics, Inc., was incorporated under the laws of the State of Delaware on January 11, 2016. The company is an RNA oncology company founded on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapies. RNA-based therapies are highly selective for their targets and have the potential to provide a range of targets in the human genome that were previously untreatable with drugs.
Company Financials
EPS
RNAZ has released its 2023 Q3 earnings. EPS was reported at -67.20, versus the expected -1.50, missing expectations. The chart below visualizes how RNAZ has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available